keyword
https://read.qxmd.com/read/38587758/targeting-strategies-with-lipid-vectors-for-nucleic-acid-supplementation-therapy-in-fabry-disease-a-systematic-review
#21
JOURNAL ARTICLE
Julen Rodríguez-Castejón, Marina Beraza-Millor, María Ángeles Solinís, Alicia Rodríguez-Gascón, Ana Del Pozo-Rodríguez
Fabry disease (FD) results from a lack of activity of the lysosomal enzyme α-Galactosidase A (α-Gal A), leading to the accumulation of glycosphingolipids in several different cell types. Protein supplementation by pDNA or mRNA delivery presents a promising strategy to tackle the underlying genetic defect in FD. Protein-coding nucleic acids in FD can be either delivered to the most affected sites by the disease, including heart, kidney and brain, or to specialized organs that can act as a production factory of the enzyme, such as the liver...
April 8, 2024: Drug Delivery and Translational Research
https://read.qxmd.com/read/38587750/drug-intervention-as-an-emerging-concept-for-secondary-prevention-in-patients-with-coronary-disease
#22
REVIEW
Yoshiyasu Minami, Junya Ako, Kenichi Tsujita, Hiroyoshi Yokoi, Yuji Ikari, Yoshihiro Morino, Yoshio Kobayashi, Ken Kozuma
Non-culprit lesion-related coronary events are a significant concern in patients with coronary artery disease (CAD) undergoing coronary intervention. Since several studies using intra-coronary imaging modalities have reported a high prevalence of vulnerable plaques in non-culprit lesions at the initial coronary event, the immediate stabilization of these plaques by intensive pharmacological regimens may contribute to the reduction in the adverse events. Although current treatment guidelines recommend the titration of statin and other drugs to attain the treatment goal of low-density lipoprotein cholesterol (LDL-C) level in patients with CAD, the early prescription of strong LDL-C lowering drugs with more intensive regimen may further reduce the incidence of recurrent cardiovascular events...
April 8, 2024: Cardiovascular Intervention and Therapeutics
https://read.qxmd.com/read/38583288/association-of-cardiovascular-health-with-subclinical-coronary-atherosclerosis-progression-among-five-racial-and-ethnic-groups-the-masala-and-mesa-studies
#23
JOURNAL ARTICLE
Vardhmaan Jain, Mahmoud Al Rifai, Alka M Kanaya, Nilay S Shah, Sameera A Talegawkar, Salim S Virani, Erin D Michos, Roger S Blumenthal, Jaideep Patel
BACKGROUND AND AIMS: South Asian adults (SA) are at higher risk for atherosclerotic cardiovascular disease (ASCVD) compared with other racial/ethnic groups. Life's Simple 7 (LS7) is a guideline-recommended, cardiovascular health (CVH) construct to guide optimization of cardiovascular risk factors. We sought to assess if the LS7 metrics predict coronary artery calcium (CAC) incidence and progression in asymptomatic SA compared with four other racial/ethnic groups. METHODS: We assessed the distribution of CVH metrics (inadequate: score 0-8, average: 9-10, optimal: 11-14, and per 1-unit higher score) and its association with incidence and progression of CAC among South Asians in the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study compared with other race/ethnic groups from the Multiethnic Study of Atherosclerosis (MESA)...
March 17, 2024: Atherosclerosis
https://read.qxmd.com/read/38581978/size-exclusion-chromatography-of-biopharmaceutical-products-from-current-practices-for-proteins-to-emerging-trends-for-viral-vectors-nucleic-acids-and-lipid-nanoparticles
#24
REVIEW
Valentina D'Atri, Mateusz Imiołek, Colette Quinn, Abraham Finny, Matthew Lauber, Szabolcs Fekete, Davy Guillarme
The 21st century has been particularly productive for the biopharmaceutical industry, with the introduction of several classes of innovative therapeutics, such as monoclonal antibodies and related compounds, gene therapy products, and RNA-based modalities. All these new molecules are susceptible to aggregation and fragmentation, which necessitates a size variant analysis for their comprehensive characterization. Size exclusion chromatography (SEC) is one of the reference techniques that can be applied. The analytical techniques for mAbs are now well established and some of them are now emerging for the newer modalities...
April 1, 2024: Journal of Chromatography. A
https://read.qxmd.com/read/38573436/unexpected-gaps-in-knowledge-of-familial-hypercholesterolaemia-among-dutch-general-practitioners
#25
JOURNAL ARTICLE
Shirin Ibrahim, Jim N de Goeij, Nick S Nurmohamed, Jing Pang, Sibbeliene E van den Bosch, Fabrice M A C Martens, Jeanine E Roeters van Lennep, Willemijn Corpeleijn, Talip Tumkaya, G Kees Hovingh, Gerald F Watts, Erik S G Stroes, Laurens F Reeskamp
BACKGROUND: Familial hypercholesterolaemia (FH) warrants early diagnosis to prevent premature atherosclerotic cardiovascular disease (CVD). However, underdiagnosis and undertreatment of FH persist. This study aimed to assess the knowledge and practice of FH care among general practitioners (GPs) in the Netherlands. METHODS: An internationally standardised, online questionnaire was sent to Dutch GPs between February 2021 and July 2022. The survey assessed knowledge and awareness of FH, encompassing general familiarity, awareness of management guidelines, inheritance, prevalence, CVD risk, and clinical practice related to FH...
April 4, 2024: Netherlands Heart Journal
https://read.qxmd.com/read/38571923/beverages-a-scoping-review-for-nordic-nutrition-recommendations-2023
#26
REVIEW
Emily Sonestedt, Marko Lukic
Background: Coffee, tea, sugar-sweetened beverages (SSBs), and low- and no-calorie sweetened beverages (LNCSBs) are generally frequently consumed in the Nordic and Baltic countries. These beverages have also been related to potential health effects. This scoping review describes the evidence for the role of coffee, tea, SSBs, and LNCSBs for health-related outcomes as a basis for setting and updating food-based dietary guidelines. We used evidence from several qualified systematic reviews (i.e. World Cancer Research Fund, US Dietary Guidelines Advisory Committee, European Food Safety Authority, and World Health Organization) and performed a search for additional systematic reviews...
2024: Food & Nutrition Research
https://read.qxmd.com/read/38571914/fish-a-scoping-review-for-nordic-nutrition-recommendations-2023
#27
REVIEW
Johanna E Torfadottir, Stine M Ulven
The aim of this scoping review was to conduct evidence-based documentation between fish intake and health outcomes for food-based dietary guidelines (FBDGs) in the Nordic Nutrition Recommendations (NNR) 2023. For most health outcomes, the evidence for fish oil and n-3 long chain (LC) polyunsaturated fatty acids (PUFA) supplementation was included when examining evidence between fish intake and health. In this review, conclusions from qualified systematic reviews (qSR) approved by NNR2023 are included. In addition, conclusions of a de novo systematic reviews on the topic of n-3 LC-PUFA, asthma, and allergy are included...
2024: Food & Nutrition Research
https://read.qxmd.com/read/38569868/obicetrapib-as-an-adjunct-to-stable-statin-therapy-in-japanese-subjects-results-from-a-randomized-phase-2-trial
#28
JOURNAL ARTICLE
Mariko Harada-Shiba, Michael H Davdison, Marc Ditmarsch, Andrew Hsieh, Erin Wuerdeman, Douglas Kling, Annie Nield, Mary R Dicklin, Akitaka Nakata, Atsushi Sueyoshi, Satoshi Kuroyanagi, John J P Kastelein
AIMS: Obicetrapib is a highly selective cholesteryl ester transfer protein (CETP) inhibitor shown to reduce low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB), when taken as monotherapy and in combination with ezetimibe on a background of statins, in clinical trials predominantly conducted in Northern European/Caucasian participants. We characterized the efficacy, safety, and tolerability of obicetrapib within an Asian-Pacific region population. METHODS: This double-blind, randomized, phase 2 trial examined obicetrapib 2...
April 3, 2024: Journal of Atherosclerosis and Thrombosis
https://read.qxmd.com/read/38569708/effectiveness-of-an-anti-inflammatory-diet-versus-low-fat-diet-for-knee-osteoarthritis-the-feast-randomised-controlled-trial-protocol
#29
JOURNAL ARTICLE
Lynette Law, Joshua L Heerey, Brooke L Devlin, Peter Brukner, Joanne L Kemp, Amanda Attanayake, Mark D Hulett, Alysha De Livera, Andrea B Mosler, Hayden G Morris, Nathan P White, Adam G Culvenor
INTRODUCTION: Chronic inflammation plays a key role in knee osteoarthritis pathophysiology and increases risk of comorbidities, yet most interventions do not typically target inflammation. Our study will investigate if an anti-inflammatory dietary programme is superior to a standard care low-fat dietary programme for improving knee pain, function and quality-of-life in people with knee osteoarthritis. METHODS AND ANALYSIS: The eFEct of an Anti-inflammatory diet for knee oSTeoarthritis study is a parallel-group, assessor-blinded, superiority randomised controlled trial...
April 2, 2024: BMJ Open
https://read.qxmd.com/read/38567808/pharmacist-optimization-of-lipid-therapy-in-patients-with-peripheral-vascular-disease
#30
JOURNAL ARTICLE
Mary-Ashlyn Tucker, Andrew Meyer, Michael Bitonti, Megan Supple, Brandon Cain
DISCLAIMER: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE: American College of Cardiology/American Heart Association guidelines recommend high-intensity statin therapy and consideration for nonstatin therapy for patients with peripheral vascular disease (PVD); however, utilization rates remain suboptimal...
April 3, 2024: American Journal of Health-system Pharmacy: AJHP
https://read.qxmd.com/read/38566225/triglyceride-to-high-density-lipoprotein-cholesterol-ratio-associated-with-long-term-adverse-clinical-outcomes-in-patients-deferred-revascularization-following-fractional-flow-reserve
#31
JOURNAL ARTICLE
Fanqi Li, Xiaofang Li, Jiabao Zhou, Qiuzhen Lin, Yong Zhou, Jiayi Zhu, Keke Wu, Donghui Zhao, Qiuyu Li, Haixiong Wang, Qiming Liu
BACKGROUND: Guidelines on coronary intermediate lesions strongly recommend deferred revascularization after detecting a normal fractional flow reserve (FFR). Researches about triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) on cardiovascular diseases has also been well conducted. However, the association of TG/HDL-C and long-term adverse clinical outcomes remains unknown for patients deferred revascularization following FFR. METHODS: This study retrospectively included 374 coronary artery disease (CAD) patients with non-significant coronary lesions diagnosed by coronary angiography (CAG) and FFR...
April 2, 2024: Lipids in Health and Disease
https://read.qxmd.com/read/38565461/a-focused-update-to-the-2019-nla-scientific-statement-on-use-of-lipoprotein-a-in-clinical-practice
#32
JOURNAL ARTICLE
Marlys L Koschinsky, Archna Bajaj, Michael B Boffa, Dave L Dixon, Keith C Ferdinand, Samuel S Gidding, Edward A Gill, Terry A Jacobson, Erin D Michos, Maya S Safarova, Daniel E Soffer, Pam R Taub, Michael J Wilkinson, Don P Wilson, Christie M Ballantyne
Since the 2019 National Lipid Association (NLA) Scientific Statement on Use of Lipoprotein(a) in Clinical Practice was issued, accumulating epidemiological data have clarified the relationship between lipoprotein(a) [Lp(a)] level and cardiovascular disease risk and risk reduction. Therefore, the NLA developed this focused update to guide clinicians in applying this emerging evidence in clinical practice. We now have sufficient evidence to support the recommendation to measure Lp(a) levels at least once in every adult for risk stratification...
March 29, 2024: Journal of Clinical Lipidology
https://read.qxmd.com/read/38563012/adaptation-and-potential-culture-of-wild-amphipods-and-mysids-as-potential-live-feed-in-aquaculture-a-review
#33
JOURNAL ARTICLE
Hidayu Suhaimi, Muhammad Irfan Abdul Rahman, Aisyah Ashaari, Mhd Ikhwanuddin, Nadiah Wan Rasdi
Live foods such as phytoplankton and zooplankton are essential food sources in aquaculture. Due to their small size, they are suitable for newly hatched larvae. Artemia and rotifer are commonly used live feeds in aquaculture; each feed has a limited dietary value, which is unsuitable for all cultured species. Whereas, copepod and cladocerans species exhibit favorable characteristics that make them viable candidates as sources of essential nutrients for hatchery operations. Due to their jerking movements, it stimulates the feeding response of fish larvae, and their various sizes make them suitable for any fish and crustacean...
2024: PeerJ
https://read.qxmd.com/read/38561841/significant-but-partial-lipoprotein-lipase-functional-loss-caused-by-a-novel-occurrence-of-rare-lpl-biallelic-variants
#34
JOURNAL ARTICLE
Yuepeng Hu, Jian-Min Chen, Han Zuo, Na Pu, Guofu Zhang, Yichen Duan, Gang Li, Zhihui Tong, Weiqin Li, Baiqiang Li, Qi Yang
BACKGROUND: Lipoprotein lipase (LPL) plays a crucial role in triglyceride hydrolysis. Rare biallelic variants in the LPL gene leading to complete or near-complete loss of function cause autosomal recessive familial chylomicronemia syndrome. However, rare biallelic LPL variants resulting in significant but partial loss of function are rarely documented. This study reports a novel occurrence of such rare biallelic LPL variants in a Chinese patient with hypertriglyceridemia-induced acute pancreatitis (HTG-AP) during pregnancy and provides an in-depth functional characterization...
April 1, 2024: Lipids in Health and Disease
https://read.qxmd.com/read/38559332/consideration-and-application-of-lipoprotein-a-in-the-risk-assessment-of-atherosclerotic-cardiovascular-disease-risk-in-adults
#35
REVIEW
Tiffany Yuen, G B John Mancini, Robert A Hegele, Glen J Pearson
Lipoprotein(a) (Lp[a]) is an low-density lipoprotein (LDL)-like particle in which apolipoprotein (apo) B is covalently bound to a plasminogen-like molecule called apo(a). A High level of Lp(a) has been demonstrated to be an independent, causal, and prevalent risk factor for atherosclerotic cardiovascular disease (ASCVD), as well as aortic valve disease, through mechanisms that promote atherogenesis, inflammation, and thrombosis. With reliable and accessible assays, Lp(a) level has been established to be associated linearly with the risk for ASCVD...
March 2024: CJC open
https://read.qxmd.com/read/38548600/-chinese-guideline-for-lipid-management-primary-care-version-2024
#36
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 28, 2024: Zhonghua Xin Xue Guan Bing za Zhi
https://read.qxmd.com/read/38548456/optimal-medical-therapy-for-stable-ischemic-heart-disease-in-2024-focus-on-blood-pressure-and-lipids
#37
REVIEW
Timothy Abrahams, Stephen J Nicholls, Adam J Nelson
Hypertension and dyslipidemia are 2 highly prevalent and modifiable risk factors in patients with stable ischemic heart disease. Multiple lines of evidence demonstrate that lowering blood pressure and low-density lipoprotein cholesterol improves clinical outcomes in patients with ischemic heart disease. Accordingly, clinical guidelines recommend intensive treatment targets for these high-risk patients. This article summarizes the pathophysiology, supporting evidence, and treatment recommendations for management of hypertension and dyslipidemia among patients with manifest ischemic heart disease and points to future research and unmet clinical needs...
May 2024: Medical Clinics of North America
https://read.qxmd.com/read/38546443/sex-differences-in-low-density-lipoprotein-cholesterol-treatment-among-young-israeli-patients-following-premature-acute-coronary-syndrome
#38
JOURNAL ARTICLE
Feras Haskiah, Karam Abdelhai, Ranin Hilu, Abid Khaskia
Introduction: Effective management of dyslipidemias is crucial for reducing morbidity and mortality among patients after acute coronary syndrome (ACS). Sex differences in dyslipidemia management after premature ACS in Israeli patients have not been extensively studied. This study aimed to investigate potential disparities between men and women in managing dyslipidemia, considering current guidelines. Methods: This retrospective cohort study examined patients who were 55 years old or younger and admitted to Meir Medical Center for ACS from January 2018 to February 2019...
March 28, 2024: Metabolic Syndrome and related Disorders
https://read.qxmd.com/read/38545781/evolocumab-treatment-in-pediatric-patients-with-homozygous-familial-hypercholesterolemia-pooled-data-from-three-open-label-studies
#39
JOURNAL ARTICLE
Frederick J Raal, Robert A Hegele, Andrea Ruzza, J Antonio G López, Ajay K Bhatia, Johnny Wu, Huei Wang, Daniel Gaudet, Albert Wiegman, Jian Wang, Raul D Santos
BACKGROUND: Pediatric patients with homozygous familial hypercholesterolemia (HoFH) have an increased risk of atherosclerotic cardiovascular disease and difficulty meeting low-density lipoprotein cholesterol (LDL-C) goals. In this post hoc analysis, we evaluated pooled safety and efficacy data from 3 studies in pediatric patients with HoFH treated with the PCSK9 (proprotein convertase subtilisin/kexin type 9) monoclonal antibody inhibitor evolocumab. METHODS: Patients with HoFH aged 10 to 17 years received treatment with open-label evolocumab 420 mg subcutaneously monthly or biweekly in the TAUSSIG, RAMAN, or HAUSER-OLE clinical studies...
March 28, 2024: Arteriosclerosis, Thrombosis, and Vascular Biology
https://read.qxmd.com/read/38543075/dyslipidemia-a-narrative-review-on-pharmacotherapy
#40
REVIEW
Lucas Lentini Herling de Oliveira, Arthur Cicupira Rodrigues de Assis, Viviane Zorzanelli Rocha Giraldez, Thiago Luis Scudeler, Paulo Rogério Soares
Dyslipidemia plays a fundamental role in the development and progression of atherosclerosis. Current guidelines for treating dyslipidemia focus on low-density lipoprotein-cholesterol (LDL-C). Despite advances in the pharmacotherapy of atherosclerosis, the most successful agents used to treat this disease-statins-remain insufficient in the primary or secondary prevention of acute myocardial infarction. Advancing therapy for hypercholesterolemia with emerging new drugs, either as monotherapy or in combination, is expected to improve cardiovascular outcomes...
February 23, 2024: Pharmaceuticals
keyword
keyword
46916
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.